Investigating Aspects of Renal Physiology and Pharmacology in Organ and Organoid Culture

  • Melanie L. Lawrence
  • Mona Elhendawi
  • Jamie A. DaviesEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1926)


Some aspects of renal physiology, in particular transport across tubular epithelia, are highly relevant to pharmacokinetics and to drug toxicity. The use of animals to model human renal physiology is limited, but human-derived renal organoids offer an alternative, relevant system in culture. Here, we explain how the activity of specific transport systems can be assessed in renal organoid and organ culture, using a system illustrated mainly for mouse but that can be extended to human organoids.

Key words

OCT OAT MRP MATE Transport Fluorescent probe 


  1. 1.
    Saxen L (1987) Organogenesis of the kidney. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  2. 2.
    Saxén L, Vainio T, Toivonen S (1962) Effect of polyoma virus on mouse kidney rudiment in vitro. J Natl Cancer Inst 29:597–631. Scholar
  3. 3.
    Saxen L (1983) In vitro model-systems for chemical teratogenesis. In: Kolber A, Wong T, Grant L et al (eds) In vitro toxicity testing of environmental agents, part B. Plenum Press, New York, pp 173–190Google Scholar
  4. 4.
    Gorboulev V, Ulzheimer JC, Akhoundova A et al (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–881CrossRefGoogle Scholar
  5. 5.
    Karbach U, Kricke J, Meyer-Wentrup F et al (2000) Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Ren Physiol 279:F679–F687CrossRefGoogle Scholar
  6. 6.
    Knight A (2008) Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Rev Recent Clin Trials 3:89–96CrossRefGoogle Scholar
  7. 7.
    Loghman-Adham M, Kiu Weber CI, Ciorciaro C et al (2012) Detection and management of nephrotoxicity during drug development. Expert Opin Drug Saf 11:581–596. Scholar
  8. 8.
    Benjamin A, da Costa AN, Delaunois A et al (2015) Renal safety pharmacology in drug discovery and development. In: Handbook of experimental pharmacology. Springer, New York, pp 323–352Google Scholar
  9. 9.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676. Scholar
  10. 10.
    Davies J (2014) Engineered renal tissue as a potential platform for pharmacokinetic and nephrotoxicity testing. Drug Discov Today 19:725–729. Scholar
  11. 11.
    Amorino GP, Fox MH (1995) Intracellular Na+ measurements using sodium green tetraacetate with flow cytometry. Cytometry 21:248–256. Scholar
  12. 12.
    Yasujima T, Ohta K, Inoue K, Yuasa H (2011) Characterization of human OCT1-mediated transport of DAPI as a fluorescent probe substrate. J Pharm Sci 100:4006–4012. Scholar
  13. 13.
    Ichida K, Hosoyamada M, Kimura H et al (2003) Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63:143–155. Scholar
  14. 14.
    Monien BH, Müller C, Bakhiya N et al (2009) Probenecid, an inhibitor of transmembrane organic anion transporters, alters tissue distribution of DNA adducts in 1-hydroxymethylpyrene-treated rats. Toxicology 262:80–85. Scholar
  15. 15.
    Schulz K, Hagos Y, Burckhardt G et al (2015) The isoquinolone derived prolyl hydroxylase inhibitor ICA is a potent substrate of the organic anion transporters 1 and 3. Nephron 131:285–289. Scholar
  16. 16.
    Whitley AC, Sweet DH, Walle T (2005) The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metab Dispos 33:1097–1100. Scholar
  17. 17.
    Enomoto A, Takeda M, Shimoda M et al (2002) Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301:797–802CrossRefGoogle Scholar
  18. 18.
    Shen H, Liu T, Morse BL et al (2015) Characterization of organic anion transporter 2 (SLC22A7): a highly efficient transporter for creatinine and species-dependent renal tubular expression. Drug Metab Dispos 43:984–993. Scholar
  19. 19.
    Hagos FT, Daood MJ, Ocque JA et al (2017) Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine. Xenobiotica 47:346–353. Scholar
  20. 20.
    Hagos Y, Stein D, Ugele B et al (2007) Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18:430–439. Scholar
  21. 21.
    Youngblood GL, Sweet DH (2004) Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol 287:F236–F244. Scholar
  22. 22.
    Tan PK, Ostertag TM, Miner JN (2016) Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep 6:34995. Scholar
  23. 23.
    Gollapudi S, Kim C, Tran B et al (1997) Probenecid reverses multidrug resistance in mutidrug resistance-associated prtoein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 40:150–158CrossRefGoogle Scholar
  24. 24.
    Bakos E, Evers R, Sinkó E et al (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760–768CrossRefGoogle Scholar
  25. 25.
    Gekeler V, Ise W, Sanders KH et al (1995) The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208:345–352. Scholar
  26. 26.
    Zhang L, Schaner ME, Giacomini KM (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286:354–361PubMedGoogle Scholar
  27. 27.
    Okuda M, Saito H, Urakami Y et al (1996) cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 224:500–507CrossRefGoogle Scholar
  28. 28.
    Shu Y, Bello CL, Mangravite LM et al (2001) Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther 299:392–398PubMedGoogle Scholar
  29. 29.
    Kimura N, Masuda S, Tanihara Y et al (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386CrossRefGoogle Scholar
  30. 30.
    Çetinkaya I, Ciarimboli G, Yalçinkaya G et al (2003) Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am J Physiol Renal Physiol 284:F293–F302. Scholar
  31. 31.
    Ito S, Kusuhara H, Yokochi M et al (2012) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:393–403. Scholar
  32. 32.
    Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–4602PubMedGoogle Scholar
  33. 33.
    Tai HL (2000) Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther 2:459–467PubMedGoogle Scholar
  34. 34.
    Kruijtzer CMF, Beijnen JH, Rosing H et al (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943–2950. Scholar
  35. 35.
    Allen JD, van Loevezijn A, Lakhai JM et al (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–425CrossRefGoogle Scholar
  36. 36.
    Wu W, Baker ME, Eraly SA et al (2009) Analysis of a large cluster of SLC22 transporter genes, including novel USTs, reveals species-specific amplification of subsets of family members. Physiol Genomics 38:116–124. Scholar
  37. 37.
    Lickteig AJ, Cheng X, Augustine LM et al (2008) Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci 83:59–64. Scholar
  38. 38.
    Masuda S, Terada T, Yonezawa A et al (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127–2135. Scholar
  39. 39.
    Harding SD, Sharman JL, Faccenda E et al (2018) The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. Scholar
  40. 40.
    Lawrence ML, Chang C-H, Davies JA (2015) Transport of organic anions and cations in murine embryonic kidney development and in serially-reaggregated engineered kidneys. Sci Rep 5:9092. Scholar
  41. 41.
    Sebinger DDR, Unbekandt M, Ganeva VV et al (2010) A novel, low-volume method for organ culture of embryonic kidneys that allows development of cortico-medullary anatomical organization. PLoS One 5:e10550. Scholar
  42. 42.
    Takasato M, Er PX, Chiu HS et al (2015) Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526:564–568. Scholar
  43. 43.
    Tsuda M, Terada T, Mizuno T et al (2009) Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280–1286. Scholar
  44. 44.
    Matsushima S, Maeda K, Inoue K et al (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555–559. Scholar
  45. 45.
    Ciarimboli G, Deuster D, Knief A et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169–1180. Scholar
  46. 46.
    Yasujima T, Ohta K-y, Inoue K et al (2010) Evaluation of 4′,6-diamidino-2-phenylindole as a fluorescent probe substrate for rapid assays of the functionality of human multidrug and toxin extrusion proteins. Drug Metab Dispos 38:715–721. Scholar
  47. 47.
    Wilmer MJ, Saleem MA, Masereeuw R et al (2010) Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 339:449–457. Scholar
  48. 48.
    Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537–7552. Scholar
  49. 49.
    Allikmets R, Schriml LM, Hutchinson A et al (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337–5339PubMedGoogle Scholar
  50. 50.
    Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28:203–228. Scholar
  51. 51.
    Mikkaichi T, Suzuki T, Onogawa T et al (2004) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101:3569–3574. Scholar
  52. 52.
    Hughes J, Crowe A (2010) Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 113:315–324CrossRefGoogle Scholar
  53. 53.
    Pavek P, Merino G, Wagenaar E et al (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144–152. Scholar
  54. 54.
    Morozova GI, Dobretsov GE, Dubur GI et al (1981) 4-(n-Dimethylaminostyryl)-1-methylpyridinium fluorescence in a living cell. Tsitologiia 23:916–923PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Melanie L. Lawrence
    • 1
  • Mona Elhendawi
    • 1
    • 2
  • Jamie A. Davies
    • 1
    Email author
  1. 1.Deanery of Biomedical SciencesUniversity of EdinburghEdinburghUK
  2. 2.Faculty of Medicine, Clinical Pathology DepartmentMansoura UniversityEl-MansouraEgypt

Personalised recommendations